Hyperthermie maligne – une mise à jour à l’intention des infirmières en soins périopératoires
Mots-clés :
hyperthermie maligne, HM, anesthésieRésumé
Cet article est un résumé de la présentation intitulée « Mises à jour concernant l’hyperthermie maligne » (“Updates on Malignant Hyperthermia”) donnée lors de la Conférence nationale 2015 de l’AIISOC, à Edmonton. Il présente les faits connus de l’hyperthermie maligne (HM), notamment la définition, les déclencheurs anesthésiques et non anesthésiques de l’HM, les signes et les symptômes ainsi que le traitement de l’HM. Il aborde également les soins à apporter à un patient susceptible de souffrir d’HM lors d’une intervention chirurgicale élective.
Références
Denborough M, Forster J, Lovell R,
Maplestone P, Villers J: Anaesthetic
deaths in a family. Br J Anaesth
; 34: 395-6.
Britt BA, Kalow W: Malignant
hyperthermia: aetiology unknown.
Can Anaesth Soc J 1970; 17: 316-30.
Denborough M: Malignant
hyperthermia. Lancet 1998; 352:
-6.
Riazi S, Larach MG, Hu C,
Wijeysundera D, Massey C, Kraeva
N: Malignant hyperthermia in
Canada: characteristics of index
anesthetics in 129 malignant
hyperthermia susceptible probands.
Anesth Analg 2014; 118: 381-7.
McCarthy T, Healy J, Heffron J,
Lehane M, Deufel T, Lehmann-
Horn F, Farrall M, Johnson K:
Localisation of the malignant
hyperthermia susceptibility locus to
human chromosome 19q12-q13.2.
Nature 1990; 343: 562-4.
Monnier N, Procaccio V, Stieglitz P,
Lunardi J: Malignant-hyperthermia
susceptibility is associated with a
mutation of the a1-subunit of the
human dihydropyridine-sensitive Ltype
voltage-dependent calciumchannel
receptor in skeletal muscle.
Am J Hum Genet 1997; 60: 1316-
Sambuughin N, Holley H, Muldoon
S, Brandom BW, de Bantel AM,
Tobin JR, Nelson TE, Goldfarb LG:
Screening of the entire ryanodine
receptor type 1 coding region for
sequence variants associated with
malignant hyperthermia
susceptibility in the North American
population. Anesthesiology 2005;
: 515-21.
Wu S, Murayama K, Minami N,
Ichihara Y, Kikuchi H, Noguchi S,
Hayashi YK, Ochiai R, Nishino I:
Malignant hyperthermia in Japan:
mutation screening of the entire
ryanodine receptor type 1 gene
coding region by direct
sequencing. Anesthesiology 2006;
: 1146-54.
Levano S, Vukcevic M, Singer M,
Matter A, Treves S, Urwyler A,
Girard T: Increasing the number of
diagnostic mutations in malignant
hyperthermia. Hum Mutat 2009;
: 590-8.
Kraeva N, Riazi S, Loke J, Frodis W,
Crossan ML, Nolan K, Kraev A,
MacLennan DH: Ryanodine
receptor type 1 gene mutations
found in the Canadian malignant
hyperthermia population. Can J
Anaesth 2011; 58: 504-13.
Brandom BW, Bina S, Wong CA,
Wallace T, Visoiu M, Isackson PJ,
Vladutiu GD, Sambuughin N,
Muldoon SM: Ryanodine receptor
type 1 gene variants in the
malignant hyperthermia-susceptible
population of the United States.
Anesth Analg 2013; 116: 1078-86.
Britt B, Kalow W. Malignant
hyperthermia: a statistical review.
Can J Anaesth 1970;17:293–315.
H. Ording, 1985 Incidence of
malignant hyperthermia
in Denmark. Anesth Analg 64 700.
Gonsalves SG, Ng D, Johnston JJ,
Teer JK, Stenson PD, Cooper DN,
Mullikin JC, Biesecker LG, NISC
Comparative Sequencing Program:
Using exome data to identify
malignant hyperthermia
susceptibility mutations.
Anesthesiology 2013; 119: 1043-53.
Monnier N, Krivosic-Horber R,
Payen J, Kozak-Ribbens G,Nivoche
Y, Adnet P, Reyford H, Lunardi J.
Presence of two different genetic
traits in malignant hyperthermia
families: implication for genetic
analysis, diagnosis, and incidence of
malignant hyperthermia
susceptibility. Anesthesiology 2002;
:1067–74.
Tobin JR, Jason DR, Challa VR,
Nelson TE, Sambuughin N:
Malignant hyperthermia and
apparent heat stroke. JAMA 2001;
: 168-9.
Groom L, Muldoon SM, Tang ZZ,
Brandom BW, Bayarsaikhan M,
Bina S, Lee HS, Qiu X, Sambuughin
N, Dirksen RT: Identical de novo
mutation in the type 1 ryanodine
receptor gene associated with fatal,
stress-induced malignant
hyperthermia in two unrelated
families. Anesthesiology 2011; 115:
-45.
Bendahan D, Kozak-Ribbens G,
Confort-Gouny S, Ghattas B,
Figarella-Branger D, Aubert M,
Cozzone PJ: A noninvasive
investigation of muscle energetics
supports similarities between
exertional heat stroke and malignant
hyperthermia. Anesth Analg 2001;
: 683-9.
Wappler F, Fiege M, Steinfath M,
Agarwal K, Scholz J, Singh S,
Matschke J, Esch JS: Evidence for
susceptibility to malignant
hyperthermia in patients with
exercise-induced rhabdomyolysis.
Anesthesiology 2001; 94: 95-100.
Sambuughin N, Capacchione J,
Blokhin A, Bayarsaikhan M, Bina S,
Muldoon S: The ryanodine receptor
type 1 gene variants in African
American men with exertional
rhabdomyolysis and malignant
hyperthermia susceptibility. Clin
Genet 2009; 76: 564-8.
Kochling A, Wappler F, Winkler G,
Schulte am Esch JS:
Rhabdomyolysis following severe
physical exercise in a patient with
predisposition to malignant
hyperthermia. Anaesth Intensive
Care 1998; 26: 315-8.
Larach MG, Localio AR, Allen GC,
Denborough MA, Ellis FR, Gronert
GA, Kaplan RF, Muldoon SM,
Nelson TE, Ording H, Rosenberg H,
Waud BE, Wedel DJ. A clinical
grading scale to predict malignant hyperthermia
susceptibility. Anesthesiology 1994; 80:771-9.
Allen GC, Larach MG, Kunselman AR: The sensitivity
and specificity of the caffeine‐halothane contracture
test: A report from the North American Malignant
Hyperthermia Registry. Anesthesiology 1998; 88: 579 -88.
Larach MG: Standardization of the caffeine halothane
muscle contracture test. Anesth Analg 1989; 69: 511-5.
Orlov D, Keith J, Rosen D, Croul S, Kraeva N, Riazi S:
Analysis of histomorphology in malignant hyperthermiasusceptible
patients. Can J Anaesth 2013; 60: 982-9.
Jones C, Bennett K, Kim TW, Bulger TF, Pollock N.
Preparation of Datex-Ohmeda Aestiva and Aisys
anaesthetic machines for use in malignant hyperthermia
susceptible patients. Anaesth Intensive Care. 2012;
(3):490-7.
Rosenberg H, Sambuughin N, Riazi S, Dirksen R.
Malignant Hyperthermia Susceptibility. In: Pagon RA,
Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean
LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens
K, editors. GeneReviews® [Internet]. Seattle (WA):
University of Washington, Seattle; 1993-2015. 2003 Dec
[updated 2013 Jan 31].
Sabouri S, Lerman J, Heard C. Effects of fresh gas flow,
tidal volume, and charcoal filters on the washout of
sevoflurane from the Datex Ohmeda® (GE) Aisys®,
Aestiva®/5, and Excel 210 SE Anesthesia Workstations.
Can J Anesth; 2014 61:935–942.
Barnes C, Stowell KM, Bulger T, Langton E, Pollock N.
Safe duration of postoperative monitoring for malignant
hyperthermia patients administered non-triggering
anaesthesia: an update. Anaesth Intensive Care. 2015
Jan;43(1):98 104.
http://www.mhaus.org/faqs/mh-and- pregnancy; accessed
Apr, 10th, 2015.
Larach MG, Hirshey Dirksen SJ, Belani KJ, Brandom
BW, Metz KM, Policastro MA. Creation of a Guide
for the Transfer of Care of the Malignant Hyperthermia
Patient from Ambulatory Surgery Centers to Receiving
Hospital Facilities. Anesth Analg 2012;114:94–100.
Larach MG, Brandom BW, Allen GC, Gronert GA,
Lehman EB. Malignant Hyperthermia Deaths Related to
Inadequate Temperature Monitoring, 2007–2012: A
Report from The North American Malignant
Hyper-thermia Registry of the Malignant Hyperthermia
Association of the United States. Anesth Analg 2014;119:
–66.}
